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Objective: To study the relationship between sleep disturbances and symptoms in patients with Parkinson’s
disease (PD).
Methods: The Parkinson’s Disease Sleep Scale-Chinese Version (PDSS-CV) was used to evaluate the sleep disturbances
of PD patients in a cross sectional study. The Unified Parkinson’s Disease Rating Scale (UPDRS) parts II-IV, and the Hoehn
& Yahr (H&Y) stage were used to determine the level of motor function in PD and the severity of PD. The Spearman
correlation and a multiple regression analysis were used to identify the relationship between sleep disturbances and
symptoms of PD. The quantities derived from the UPDRS and the H&Y stage and disease duration were compared
between groups of patients either with or without sleep disturbances identified by the PDSS. This study was conducted
from December 2011 to March 2012 at the First Affiliated Hospital of Sun Yat-sen University, in Guangzhou.
Results: A total of 136 PD patients were included in this study. The overall total PDSS score in PD patients was
107.58 ± 23.35 points (range: 30–146). There were significant differences in the disease duration, the H&Y stage,
and the UPDRS section subscores between groups of patients either with or without sleep disturbances (Kruskal-Wallis
Test, p <0.05). There were significant negative correlations between PDSS scores and the UPDRS subscores, the H&Y
stage and the disease duration (Spearman correlation, p < 0.05). The multiple regression analysis indicated that sleep
disturbances identified by the PDSS were only associated with daily life activity, tremor intensity and clinical fluctuation
(R2 = 0.22, F(3,132) = 12.4, p < 0.001). The correlations were also significant when the contribution of the other two
factors was excluded using partial correlations.
Conclusions: The level of daily life activity and the occurrences of tremor and clinical fluctuation are likely to be
important factors that lead to PD patients’ sleep disturbances. This study may elucidate an important clue for the
relationship between sleep disturbances and PD symptoms.
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Parkinson’s disease (PD) is the second most common neu-
rodegenerative disorder in the world. This disease is char-
acterized by both motor dysfunction and non-motor
symptoms such as sleep problems and mood abnormal-
ities. Community studies have reported that 60-98% of PD
patients have a sleep disorder [1]. One study showed that
the prevalence of PSG-quantified sleep disturbances in a
multi-ethnic Asian population with PD was 81% [2]. The
prevalence of sleep disturbances is high, yet the occur-
rence of active complaints in the clinic is uncommon, sug-
gesting that sleep disturbances are often under-recognized
and do not receive adequate treatment in PD patient in
China.
PD is one of many incurable chronic disorders, so the
aim of therapy in these patients is to improve their quality
of life (QoL). Neuropsychiatric symptoms, especially de-
pression, nighttime sleep disorders, motor fluctuations,
and unpredictable fluctuations are the variables that most
affect the QoL of patients with PD [3]. These variables
may interact with each other. The RECOVER trial showed
that treatment with rotigotine in PD patients resulted in
significant benefits in control of both motor function and
nocturnal sleep disturbances [4]. Some PD patients re-
portedly experience ‘sleep benefit’: an improved motor
functioning upon awaking in the morning [5,6]. Previous
studies have indicated that PD symptoms may contribute
to sleep disorders [7,8]. The treatment of PD with levo-
dopa preparations can improve sleep quality in PD pa-
tients [9]. Recent studies demonstrated that individual
suffering from rapid eye movement (REM) sleep behavior
disorder (RBD) carry a high specific risk (up to 80%) for
developing a neurodegenerative disorder of α- synucleino-
pathy (e.g. Parkinson’s disease, dementia with Lewy bodies
and multiple system atrophy) within 10–20 years [10].
These results show that there are some associations be-
tween PD motor symptoms and sleep disturbances. The
identification of sleep disturbances and impaired motor
function or complications of therapy will help us to im-
prove our treatment approach to achieve the main goal of
improving the QoL of our patients.
The Parkinson’s Disease Sleep Scale (PDSS) was pro-
posed by Chaudhuri and his colleagues [11]. This scale
is a disease-specific instrument that can quantify the
most common sleep problems in PD patients; the PDSS
can also identify sleep disturbances that had not been
previously diagnosed, such as sleep-maintenance insom-
nia and excessive daytime sleepiness [12]. The PDSS
provides an objective method for assessing sleep quality
in PD patients across countries with different cultures
[13]. This bedside tool has been translated into simpli-
fied Chinese and validated in China [12].
In the present study, the relationships between sleep dis-
turbances and impaired motor function and complicationsof therapy were investigated using the Chinese version of
the PDSS and the UPDRS in Chinese PD patients.Patients and methods
This is a cross-sectional study. A total of 136 consecutive
PD patients (85 male, 62.5%) participated in this survey in
our hospital during the period from December 2011 to
March 2012. The diagnoses of PD were based on the UK
Parkinson’s Disease Society Brain Bank clinical diagnostic
criteria [14]. Any patients receiving deep brain stimula-
tion or psychotropic treatments or presenting with de-
mentia, Parkinsonism, progressive supranuclear palsy,
multiple system atrophy or other psychiatric diseases
were excluded. This study was approved by the Ethic
Committee of the First Affiliated Hospital, Sun Yat-sen
University, and informed consent was obtained from all
of the participants.
The sleep disturbances were evaluated using the Chinese
version of the PDSS [12]. The PDSS was used to evaluate
the patients’ experiences over the previous week. The
PDSS consists of 15 items and reports the overall quality
of a night’s sleep (item 1), sleep onset and maintenance in-
somnia (items 2 and 3), nocturnal restlessness (items 4
and 5), nocturnal psychosis (items 6 and 7), nocturia
(items 8 and 9), nocturnal motor symptoms (items 10–13),
sleep refreshment (item 14), and daytime dozing (item 15)
[11]. The possible score for each item ranges from 0
(symptoms are severe and constant) to 10 (symptom-free).
The maximum possible cumulative score for the PDSS is
150. Scores of 105 or higher suggest normal sleep, and
scores of 90 or less suggest the presence of sleep distur-
bances [15]. A score of less than five on any item indicated
a severe sleep disturbance [16].
The Unified Parkinson’s Disease Rating Scale (UPDRS)
is a widely used clinical tool that assesses functional sta-
tus and motor performance. To analyze the possible as-
sociations between the characteristics of PD and sleep
problems, the following clinical measurements were taken:
the level of daily life activity (UPDRS part II); the occur-
rence of motor-symptom subgroups, such as tremor
(UPDRS part III, questions 20 and 21), rigidity (question
22), bradykinesia (questions 23–26 and 31), gait and pos-
tural stability (questions 27–30), bulbar abnormalities
(questions 18 and 19); and motor complications of ther-
apy, such as motor fluctuation (questions 36–39) and dys-
kinesia (questions 32–34) [17].
To compare the efficacies of different medicines directly,
the daily L-dopa equivalent dose(LED) was calculated on
the basis of the following equivalences: 100 mg of stand-
ard L-dopa equals 140 mg of controlled release L-dopa,
10 mg of selegiline, 1 mg of pramipexole, 1 mg of pergo-
lide, 10 mg of bromocriptine, and 100 mg of piribedil.
Then, the summed standard levodopa dose and levodopa
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the patient was taking entacapone [18,19].
The data were analyzed using SPSS 17.0 for Windows
(Chicago, IL). The total mean scores for the PDSS were
calculated. Correlations between PDSS scores and the
following variables: age, the H&Y stage, the disease dur-
ation, the level of daily life activity, and the occurrences
of motor symptoms and drug complications, were ex-
amined. A multiple linear regression analysis was used
to evaluate the contribution of each factor for sleep distur-
bances using a stepwise method. The variables which were
significantly associated with sleep disturbances were com-
pared in the group of patients split in three classes accord-
ing to a cut-off value for PDSS (PDSS ≤90, PDSS 91–104,
PDSS ≥105) using the Kruskal-Wallis Test. A significance
level of 0.05 was chosen.
Results
The age of the patients was 64.21 ± 11.48 years old, and
the disease duration was 5.98 ± 5.04 years. The severity
of PD was as follows: H&Y stage, 2.15 ± 0.82; UPDRS
scores (parts II to IV), 42.51 ± 23.26.
The total PDSS score in PD patients was 107.58 ± 23.35
points (range: 30–146). Overall, 26 patients (19.1%) had
sleep disturbances (a PDSS score of less than 90), 86 pa-
tients (63.2%) had normal sleep (a PDSS score of more
than 105), and 24 patients (17.6%) had possible sleep dis-
turbances (a PDSS score between 90 and 105). The preva-
lence of sleep disturbances identified by PDSS increased
with the disease severity (Table 1): 3 out of 28 patients
(10.7%) when H&Y = 1; 8 out of 68 patients (11.8%) when
H&Y= 2; 11 out of 31 patients (35.5%) when H&Y = 3; 4
out of 9 patients (44.4%) when H&Y = 4. Nocturia (item 8,
55 out of 136 patients (40.4%), mean, 4.98 ± 3.70), daytimeTable 1 The prevalence of sleep disturbances identified
by the PDSS with different disease severity
H&Y stage H&Y = 1 H&Y = 2 H&Y = 3 H&Y = 4 total
PDSS score
<90 3 8 11 4 26
PDSS group % 11.5% 30.8% 42.3% 15.4% 100.0%
H&Y stage % 10.7% 11.8% 35.5% 44.4% 19.1%
90 ~ 105 2 13 7 2 24
PDSS group % 8.3% 54.2% 29.2% 8.3% 100.0%
H&Y stage % 7.1% 19.1% 22.6% 22.2% 17.6%
>105 23 47 13 3 86
PDSS group % 26.7% 54.7% 15.1% 3.5% 100.0%
H&Y stage % 82.1% 69.1% 41.9% 33.3% 63.2%
total 28 68 31 9 136
PDSS group % 20.6% 50.0% 22.8% 6.6% 100.0%
H&Y stage % 100.0% 100.0% 100.0% 100.0% 100.0%sleep (item 15, 40 out of 136 patients (29.4%), mean, 5.9 ±
3.08) and sleep maintenance insomnia (item 3, 40 out of
136 patients (29.4%), with a mean, 6.04 ± 2.30) were the
three most severe symptoms that were reported to cause
sleep disturbances.
The differences in the disease duration, the H&Y stage,
the UPDRS scores and subscores were significant between
groups of patients either with or without sleep distur-
bances identified by PDSS (Kruskal-Wallis Test, p <0.05),
whereas the differences in bradykinesia and dyskinesia
were not (Table 2). The patients with more marked sleep
disturbances had longer disease durations, more severe
PD symptoms (as measured by H&Y stage), and higher
UPDRS scores.
There were significant negative correlations between
the PDSS scores and the disease duration (r = −0.298,
p <0.001), the H&Y stage (r = −0.308, p <0.001) and all
UPDRS subscores, including the level of daily living
activity (UPDRS II, r = −0.290, p =0.001), and the oc-
currences of motor dysfunction (UPDRS III, r = −0.234,
p =0.006) and complication (UPDRS IV, r = −0.436,
p <0.001). A univariate regression analysis showed that
the PDSS score was correlated with all of the examined
parameters (Table 3).
We ran a regression model that used the PDSS score
as the dependent variable, and the H&Y stage, the dis-
ease duration, the levodopa dosage, the daily life activity,
motor symptoms and drug complications as independent
variables. A multiple regression analysis showed signifi-
cant effects for only the level of daily life activity and the
occurrences of tremors and clinical fluctuation (R2 = 0.22,
F(3,132) = 12.4, p < 0.001) (Table 4). The other variables
did not correlate with the PDSS scores, therefore, they
were excluded from the model. Furthermore, partial
correlations indicated that significant correlations were
found between the PDSS scores and each one of the
above three factors (the level of daily life activity, the oc-
currences of tremors and clinical fluctuation) when the
contributions of the two other variables were excluded
(p <0.05).
Discussion
To our knowledge, this study is the first to estimate the
correlation between sleep disturbances identified with the
PDSS and the PD symptoms evaluated by the UPDRS.
It has been shown that the PDSS is a good scale for
quantifying sleep disturbances in PD patients, and it is be-
coming used increasingly in the PD field in Asia because
of its excellent test–retest reliability and easy application
[2,12,20]. Thus, the PDSS was used to identify sleep dis-
turbances in the present study. The total PDSS score in
PD patients was 107.58 ± 23.35 points, compatible with
other cross-sectional study using PDSS [3,12,16,21,22].
Scores of 90 or less suggest the presence of sleep
Table 2 The differences of the disease duration, the H&Y stage, the L-dopa equivalent dose, and the UPDRS scores and
subscores among PDSS-identified sleep disturbances
items Groups
Score ≤ 90 (n = 26) 91 ~ 104(n = 24) ≥105(n = 86)
Mean (SD) Min-Max Mean (SD) Min-Max Mean (SD) Min-Max
Male. n (%) 15(17.6) 15(17.6) 55(64.7)
Age at visit, years 63.42(2.68) 34-87 70.42(1.48) 51-88 62.71(1.22) 29-80
Age at onset, years 54.21(2.84) 27.5-81 64.54(1.97) 40-81 57.68(1.27) 27.5-78
Disease duration** 9.21(6.14) 0.5-27 5.88(5.59) 1-27 5.03(4.09) 0.5-20
H&Y stage** 2.62(0.90) 1-4 2.38(0.77) 1-4 1.95(0.75) 1-4
Levodopa* 494(208) 100-950 339(233) 0-786 360(261) 0-1196
UPDRS score** 56.19(29.93) 19-141 48.46(26.75) 18-121 36.72(17.36) 10-111
Daily life activity* 16.85(8.68) 6-41 14.96(8.93) 6-37 11.44(5.11) 3-33
Motor function** 36.27(21.06) 3-91 32.33(18.27) 10-83 24.00(12.30) 4-73
Tremor* 5.96(5.42) 0-20 5.58(3.87) 0-15 3.53(3.05) 0-14
Rigidity** 8.46(4.55) 0-19 6.17(4.58) 0-17 5.26(3.44) 0-15
bradykinesia 13.54(8.58) 1-30 12.04(8.61) 1-36 9.27(6.23) 0-36
Gait/postural stability* 5.23(3.73) 0-15 5.38(3.82) 0-16 3.61(2.95) 0-16
Bulbar abnormalities** 3.08(1.35) 1-7 3.17(1.63) 0-8 2.33(0.99) 0-5
Complication** 3.08(2.62) 0-9 1.17(1.09) 0-4 1.28(1.97) 0-11
Motor fluctuation** 1.46(1.96) 0-7 0.04(0.2) 0-1 0.44(1.06) 0-4
Dyskinesia 0.50(1.03) 0-4 0.17(0.64) 0-3 0.26(0.84) 0-6
*:p < 0.05; **:p < 0.01. Kruskal-Wallis Test, max =maximum; min =minimum.
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frequency of sleep disturbances detected by the PDSS
in the current study was 20%, which was similar to
Porter’s study [15].
In the present study, we found that the PDSS-identified
sleep disturbances correlated with all the examined pa-
rameters. Interestingly, further study using multiple re-
gression analysis revealed that only the level of daily life
activity and the occurrences of tremor and clinical fluctu-
ation had stable associations with the PDSS scores. TheTable 3 A univariate analysis of the factors associated with th
Variable Regression coefficient 95% CI
Disease duration −1.346 −2.103 to −0.589
HY stage −9.57 −14.125 to −5.016
levodopa −0.016 −0.031 to 0.000
Daily life activity −1.274 −1.8 to −0.747
Tremor −1.994 −2.965 to −1.024
Rigidity −1.918 −2.848 to −0.988
Bradykinesia −0.913 −1.487 to −0.338
Gait/postural stability −2.009 −3.15 to −0.868
Bulbar abnormality −4.812 −7.902 to −1.721
Motor fluctuation −5.135 −8.124 to −2.146
Dyskinesia −3.18 −7.385 to 1.476
The regression coefficient is an unstandardized beta weight and the standardized ccorrelations were also significant even when using partial
correlations excluding the contribution of the other two
factors.
The PDSS score correlated with the daily life activity
score. Correlations between sleep disturbances and daily
life activity have been reported previously for various
diseases. For example, in depressed patients, insomnia is
associated with poor health-related quality of life. The
treatment of insomnia in depressed patients produced
superior improvement in the health-related quality of lifee PDSS scores
Standardized coefficient t-score p-value R2
−0.291 −3.517 0.001 0.085
−0.338 −4.156 0.000 0.114
−0.171 −2.004 0.047 0.029
−0.382 −4.785 0.000 0.146
−0.331 −4.065 0.000 0.11
−0.332 −4.08 0.000 0.11
−0.262 −3.142 0.002 0.069
−0.288 −3.481 0.001 0.083
−0.257 −3.079 0.003 0.066
−0.282 −3.398 0.001 0.079
−0.116 −1.351 0.179 0.013
oefficient is a beta weight as well; CI = confidence interval.
Table 4 A multiple regression analysis of the factors associated with the PDSS scores (R2 = 0.22,F(3,132) = 12.4,
p < 0.001)
Variable Regression coefficient 95% CI Standardized coefficient t-score p-value
Daily life activity −0.716 −1.325 to −0.107 −0.215 −2.325 0.022
Tremor −1.346 −2.41 to −0.281 −0.224 −2.501 0.005
Motor fluctuation −4.131 −7.023 to −1.239 −0.227 −2.826 0.005
CI = confidence interval.
Zhou et al. Translational Neurodegeneration 2014, 3:21 Page 5 of 7
http://www.translationalneurodegeneration.com/content/3/1/21[23]. In dementia patients, sleep disturbances were also
associated with decreased daily activity [24]. Our results
supported this idea by showing that the prevalence of
sleep disturbances identified by the PDSS increased with
the disease severity (Table 1). Research has revealed that
impaired bed mobility seemed to be the reasons that the
sleep disturbances correlated with daily life activity. Stack
& Ashburn [7] evaluated the sleep of 38 people with PD
and observed their turning strategies and found that most
reported difficulty maintaining sleep and difficulty turning.
Using multiple strategies they found impaired bed mobility
was associated with sleep disturbance [7]. Recently Louter’s
study also found that subjectively impaired bed mobility
in Parkinson disease affects sleep efficiency [8]. Therefore,
treatment strategies designed to improve bed mobility
may help improve sleep quality.
The PDSS score was associated with tremor but not
with other PD motor symptoms. Motor symptoms such
as tremor, rigidity, and bradykinesia have been shown to
cause sleep fragmentation [25], whereas improving motor
function in PD patients can alleviate some sleep problems
[20,26]. The sleep disturbances resulting from the appear-
ance of PD symptoms can occur during any sleep stage,
but they are most common in light sleep [27]. Patients
with PD may be more sensitive to tremor than other
symptoms during sleep. Tremor is associated with awak-
enings, microarousals, body movements and sleep-state
changes [25]. In the light-sleep stage, tremor may affect
the comfort of PD patients, induce frequent and pro-
longed awakenings, disrupt sleep continuity, and cause
sleep fragmentation. PD patients may complain of an in-
ability to fall back to sleep. The relationship between the
PDSS score and tremor suggested that tremor, but not the
other motor symptoms, likely plays the most critical role
in PD sleep disorders.
In our study, sleep disturbances were correlated with
motor fluctuation during sleep. A logistic regression
analysis with sleep quality as the dependent variable re-
vealed that the on/off phenomena is associated with
sleep disturbances in PD patients [28]. Patients with PD
may have difficulties turning over in bed in the unpre-
dictable “off” state and difficulties turning over in bed
are one cause of nocturnal awakening [29].
The level of medication is an important factor for
sleep disturbance in PD [30,31]. In the present study, weused the levodopa equivalent dose(LED) to compare the
efficacies of different medicines directly. Surprisingly, in
the multiple regression analysis using the PDSS scores
as the dependent variable, only activity of daily living,
tremor and clinical fluctuations were significantly corre-
lated with sleep disturbance. In cross-sectional studies,
the relationships between sleep disturbances and dopa-
minergic medications are not clear. Our result is similar
with Pellecchia’s study in Italian PD patients [21]. Sleep
quality in patients who took dopaminergic agonists did
not differ from that of patients who took levodopa in
monotherapy [32]. Stefansdottir’s study [33] also shows
only minor changes in PDSS scores in PD patients be-
fore and after the introduction of dopaminergic treat-
ment (levodopa, dopamine agonists or MAO-B inhibitor
alone or in combination with one of the other). Changes
in PDSS total and subdomain scores from baseline to
follow-up did not differ between the levodopa and dopa-
mine agonist groups [33]. Influence of medication on
sleep in PD is complex and drug treatment itself may have
either negative or positive impact on sleep quality [34].
Lower doses of dopamine agonists can improve sleep
quality partly by reducing motor symptoms [35,36]. How-
ever, the same drugs may cause insomnia and excessive
daytime sleepiness [37]. Our result suggests that the medi-
cations’ effects on sleep disturbances were non-significant,
at least in this study.
There are some limitations in this study. First, disease
duration was not included in selection criteria and this is
a limitation because disease duration is critical to properly
diagnose PD. Accuracy for PD diagnosis in patients with
less than 5 years of disease is about 26-53% [38]. All cases
in this study were examined by a group of movement dis-
order specialists and had improvement when treated with
dopaminergic medications, which may improve the accur-
acy of PD diagnosis. Second, depression was not assessed
in this study. The relationship among depression, sleep
disorders and PD is very complicated. Depression can
affect sleep and is prevalent among PD patients [34].
Major depressive disorder been associated with an in-
creased risk of subsequent PD [39]. One study aiming to
quantify sleep problems in PD patients shows antidepres-
sive drugs had no effect on the scores obtained through
the PDSS scale [32]. In the future, we should consider the
effect of depression when designing a new study about
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of specific medications that could affect sleep was not per-
formed. However, as discussed on the above paragraph,
using of levodopa equivalent dose(LED) limits potential
impact of other medications on sleep in this study also
can provide helpful information for us in some degree.
Conclusions
In this study, approximately 20% of PD patients were
found to be suffering from sleep disturbances. The signifi-
cant correlations between sleep disorders and the variables
of the level of daily life activity and the occurrences of
tremor and clinical fluctuation (but not with disease dur-
ation, H&Y stage, levodopa and all the other PD symp-
toms) suggests that daily life activity, tremor and clinical
fluctuation are likely to be important factors that lead to
PD patients’ sleep disturbances. This study provides im-
portant information about the relationship between sleep
disturbances and PD symptoms.
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